Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Data Show Zepbound Reduces Type 2 Diabetes Risk Long Term

Aug 20 2024

• By Joseph Haas

Preventive medicine — Lilly reports data showing a diabetes prevention benefit with tirzepatide • Source: Shutterstock

Related Content

Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call

Apr 28 2022

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Apr 17 2024

Lilly Plans ‘Big, Bold’ Launch For Zepbound

Nov 08 2023

Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial

Apr 24 2023

Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights

Apr 06 2023

Lilly’s Tirzepatide Shows Benefit In Heart Failure, Including Outcomes

Aug 01 2024

Novo Pulls Wegovy Heart Failure Application, Will Resubmit To Get ‘Hard Endpoints’ In Label

Aug 08 2024

Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn

Aug 08 2024

Related Companies

Eli Lilly and Company

Novo Nordisk A/S

Additional Topics

Clinical Trials Business Strategies Drug Approval Standards Research & Development Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window